Abstract
Commercial development of the anti‐cancer drug taxol has involved a complex set of interlocking research agreements. This paper explores the implications of such agreements and discusses diverse policy issues surrounding taxol development. Among these are forest management, species preservation, intellectual property rights, and the economics of biomedical research. Advances in genetic research increasingly have linked natural resource and technology policy issues. Institutional innovations in public/private research arrangements play a vital role in biotechnology development but are poorly understood. Policymakers need formal analyses of such agreements in order to evaluate complex research programs.
Original language | English (US) |
---|---|
Pages (from-to) | 1-11 |
Number of pages | 11 |
Journal | Contemporary Economic Policy |
Volume | 11 |
Issue number | 3 |
DOIs | |
State | Published - Jul 1993 |
Externally published | Yes |
ASJC Scopus subject areas
- General Business, Management and Accounting
- Economics and Econometrics
- Public Administration